
ChemoINTELTM: A high-throughput, multi-parametric compound screening platform for intelligent lead compound and therapeutic combination identification. Kellye C. Kirkbride¹, Kevin J. Polach¹, Samantha J. Braxton¹, Megan D. Hoeksema¹, Dustin C. Rogers¹, Patricia Ladd-Ward¹, Durdica Vojnic Zelic¹, Santosh Putta², Matt Westfall¹, Norman Purvis¹

¹Pierian Biosciences, Franklin, TN, USA; ²Qognit,Inc., San Carlos, CA, USA

RESULTS

ABSTRACT

Pierian Biosciences has developed the ChemoINTEL[™] platform for high-throughput, semiautomated quantification of cellular responses to chemotherapeutics. ChemoINTEL[™] relies on a microscopy-based process that captures and analyzes single cell behavior to reflect responses within a population. The platform is customizable to a variety of small molecule panels, either specific to certain tumor types or for titration screening of small molecules in development. Automated imaging of each well of a 384-well plate over time provides realtime kinetic response data under a variety of treatment conditions. Brightfield and fluorescent images are used to determine quantitative changes in morphology and molecular metrics reflecting induced apoptosis and cell death. Unique to ChemoINTEL[™] as a drug screening platform is the quantification of intensity values of each fluorescent probe at each timepoint through a high-throughput analysis routine. These data are further processed through an internally developed algorithm to compare a treated population's response relative to an untreated control and reports a sensitivity score. By combining different treatment conditions, the platform provides intelligent design of single agent or combination treatment approaches. By capturing images of the population versus whole well population-based absorbance data, ChemoINTEL[™] aids in better understanding response of tumor cell sub-populations to different chemotherapeutic agents. As a compound library screening tool or potential clinical diagnostic, Pierian Biosciences' quality-controlled processes ensure all of its equipment, reagents and processes follow ISO17025 guidelines to ensure the quality of all data generated. Each assay is internally controlled to include a standard cell line, whose response is monitored for accuracy of the reported results. In collaboration with several biorepositories and through the development of a standardized dissociation approach resulting in purification of viable primary tumor cells, the ChemoINTEL[™] platform is also under development to assess chemotherapeutic response within patient populations. In addition to the ChemoINTEL model platform, Pierian Biosciences has also developed a sophisticated multi-color flow cytometry platform (ImmunoINTEL[™]) that when used in conjunction with ChemoINTEL[™] provides information on the purity of isolated primary tumor cells prior to plating, as well as information on the cell populations present within the tumor microenvironment. These two platforms can be further complexed to evaluate immunotherapies in combination with front-line therapies. In summary, Pierian Biosciences has developed a high-throughput, multi-parametric platform for both drug development and diagnostic applications.



Introduction and Objectives

- Development of a high-throughput compound screening platform to support biopharmaceutical initial target validation, clinical trial development, and commercial launch
- DeliverHigh-throughput imaging system for assessment of apoptotic responses via fluorescent reporter activity
- Provide services in a highly automated and regulated fashion under ISO 17025 certification
- Combine with multi-parametric flow cytometry to further evaluate functional/molecular biomarkers
- Provide ever increasing insight into biology as related to drug activity and disease characterization

cellular response to chemotherapy. **Jntreated** (Control) 100.00 Treatment induced apoptosis Drug3 Spontaneous 70.00 apoptosis 60.00 Treatment 40 induced Treated apoptosis 10.00 -Time (Hours) 4 5 6 7 8 9 10 11 12 13 20 Time (Hours) Luciferase Assay **ChemoINTEL[™] Assay UM** Drug 3 Drug 5 Drug 5

CEG

2D plots of single cell

data


Automated Single

Cell Identification

A. One-dimensional graphical representation of percent dead across a number of timepoints. **B**. Representative example of ChemoINTEL[™] treatment induced apoptosis measurements. **C.** ChemoINTEL[™] results were compared to a luciferase-based endpoint viability measurement demonstrating the accuracy and sensitivity of the ChemoINTEL[™] platform.

Figure 4. Optimized drug concentrations & lead compound identification utilizing the ChemoINTEL[™] platform


Drug 3



i y 101	
pic &	Cryopreservation for
assays	subsequent use


1) A solid tumor mass is converted to 3) a single cell suspension through a 2) semi-automated dissociation process involving chemical and mechanical digestion resulting in high viability of the heterogenous tumor. The post-digestion material is then further enriched through 4) an automated cell separation process to generate two populations of cells 5) an enriched viable epithelial tumor cells for plating and **6**) a depleted fraction containing fibroblasts, immune cells and red blood cells

Figure 7. ChemoINTELTM in combination with flow cytometry verifies purity of isolated tumor cell population (Abstract 1361 for more information).



A. Single cell suspensions from digested solid tumors are stained for epithelial cell markers (CD326+, shown), tumor-infiltrating lymphocytes (CD45+, shown) and other cell populations (not shown). B. A semi-automated processes enriches for viable epithelial tumor cells and C. the depleted fraction contains the TILs

Figure 8. ChemoINTELTM is used to assay drug response in enriched human tumor cells.





Methods and Workflow

The ChemoINTEL[™] platform utilizes a semi-automated process for sample preparation, plating, and imaging

Pre-Analytical Steps	Sample Processing	Analytical Steps
 Sample collection Sample shipment Sample receipt and accessioning 	 Hamilton Liquid Handling (plating and drug treatment) BioTek BiosSpa 8 Automated Incubator BioTek Cytation5 real-time kinetic imaging 	 Sample Acquisition: automated imaging and Flow Cytometry Automated gating


Figure 1. Pierian Biosciences ChemoINTEL[™] platform utilizes kinetic live-cell Imaging






A. Determining the EC_{50} value of different small molecule inhibitors at different time points through 12pt serial titrations. **B.** Comparison of the kinetics of the cellular response to multiple different drugs at different timepoint. C. Assessment of the effect of different drugs on cell viability in different cell populations as represented by the two cell lines.

Figure 5. Custom Plate Design Allows for Easy Drug Combination Testing





Enriched tumor cells are treated with chemotherapeutic agents, both single and in combination, and fluorescent probes for real-time imaging of cell viability and drug-induced apoptosis. The amount of drug-induced apoptosis in treated cells is calculated and plotted as a function of time.

CONCLUSIONS

- Pierian Biosciences has developed a high-throughput, semi-automated, multi-parametric platform intended for use in both drug development and diagnostic applications
- The ChemoINTEL[™] platform provides detailed information about effective concentrations and kinetic profiles
- The downstream software-based HTP analysis accelerates data analysis/extraction and increases the quality of data obtained from cell line based work or patient-derived specimens
- The ChemoINTEL[™] platform can serve as a drug discovery/evaluation tool (a) in early stage drug development; (b) for patient stratification in clinical trials; (c) for identifying the most effective treatment regiment in the clinic

FOR MORE INFORMATION

The percentage of non-apoptotic (live) cells plotted as a function of time. Live cell frequency calculated for each assay point as the double negative population (BOBO1-, CEG-)

• Website: www.pierianbio.com

• US Headquarters: 405 Duke Drive, Suite 240, Franklin, TN 37067

• Toll Free: (877) 434-2832; Fax: (615) 567-0201 • Email: kkirkbride@pierianbio.com

• Clinicians & Partners - Email: info@pierianbio.com

